<DOC>
	<DOCNO>NCT03086564</DOCNO>
	<brief_summary>The effect anti-tumor treatment satisfy HBV-related hepatocellular carcinoma ( HBV-HCC ) reason HBV-HCC carry highly heterogeneous antigen facilitate cancer cell escape immune surveillance construct immunosuppressive microenvironment . Correspondingly , dendritic cell activate HBV antigen peptide HepG2 cell protein lysate efficiently present T cell antigens HCC sensitize antitumor property meanwhile cyclophosphamide ( CY ) effectively improve microenvironment immunity . Therefore , put forward new scientific therapy call `` Activated Dendritic-cells Combined Cyclophosphamide '' ( ADCC ) combine TACE patient advance hepatocellular carcinoma prolong survival time .</brief_summary>
	<brief_title>A Basic-clinical Translational Research Hepatitis B Virus ( HBV ) -Specific Antigen Peptides HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization ( TACE ) HBV-related HCC Treatment ( BTRHBVAPHCLCDCCTCHBVHCCT )</brief_title>
	<detailed_description>Patients good compliance comply inclusion criterion enrol research . The 70 patient randomly assign experimental group control group ratio 1:1 , one group ( control group ) go receive TACE treatment solely ; another group ( experimental group ) enrollment receive TACE first course.Then 10ml blood take activated dendritic cell culture.CY treatment performed patient reasonable dose two day second TACE.The day second TACE perform , patient receive activated-dendritic cell simultaneously . 31 day first TACE therapy , patient determine continue additional course monitoring blood parameter , tumor indicator image examination . Additionally , set treatment course contain 31 day go change one course 93 day third course .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<criteria>Patients history hepatitis B infection Stage B C Barcelona Clinic Liver Cancer ( BCLC ) Eastern Cooperative Oncology Group ( ECOG ) score &lt; = 2 . ( without portal vein involve ) Patients unable perform surgery liver transplant Patients appropriate perform TACE 18 18 year old Patients n't receive radiation therapy chemotherapy immunotherapy Normal renal function Blood routine test : Hb &gt; =9g/L , white cell count &gt; =1.5*10^9/L , platelet count &gt; =50*10^9 Liver function : bilirubin &lt; =50ummol/L , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; =5 time upper limit normal ChildPugh score &lt; =9 Human Chorionic Gonadotropin ( HCG ) test negative ( ) patient woman reproductive age Women reproductive age promise contracept therapy course finish 3 month Patients sign informed consent Extrahepatic metastasis hepatocellular carcinoma History embolism , chemotherapy radiation History major surgery last 4 week History radiofrequency ablation last 6 week Acute infection last 2 week ChildPugh score &gt; 9 Patients hepatic encephalopathy Patients ascites needed drainage HCC portal vein involve Patients history cancer Patients history HIV Pregnant woman Patients severe disease like cardiac dysfunction Patients mental illness influence signing inform consent HBV infection combine type hepatitis Patients autoimmune disease Immunosuppressant drug user Patients follow trial principle</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HCC</keyword>
	<keyword>ADCC</keyword>
	<keyword>TACE</keyword>
	<keyword>immuno therapy</keyword>
</DOC>